000064386 001__ 64386
000064386 005__ 20190709135618.0
000064386 0247_ $$2doi$$a10.18632/oncotarget.21528
000064386 0248_ $$2sideral$$a103840
000064386 037__ $$aART-2017-103840
000064386 041__ $$aeng
000064386 100__ $$aLué, Alberto
000064386 245__ $$aNeutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib
000064386 260__ $$c2017
000064386 5060_ $$aAccess copy available to the general public$$fUnrestricted
000064386 5203_ $$aNeutrophil-to-lymphocyte ratio (NLR) is considered a prognostic factor in patients with hepatocellular carcinoma (HCC). Our aim is to investigate the prognostic significance of NLR in patients with HCC treated with sorafenib.
Results
Median follow-up time was 7 months. Patients were mostly in the intermediate (27.3%) or advanced (72.7%) BCLC stages, 38.6% had vascular invasion and 27.5% extrahepatic disease. A large proportion (38.9%) had been previously treated with TACE. Liver function was preserved: 65.8% were classed as Child A. Median overall survival was 7.7 months (95% CI: 5.8–9.6). In univariate analysis, vascular invasion (P = 0.004), ECOG-PS = 1 (P < 0.001), high bilirubin (P < 0.001), clinical ascites (P = 0.036), BCLC stage (P = 0.004), no previous TACE (P = 0.041) and NRL = 2.3 (P = 0.005) were predictors of poor survival. Skin toxicity (P = 0.039) or hypertension (P = 0.033) during treatment were related to better survival. In multivariate analysis NLR = 2.3 [HR 1.72 (95% CI: 1.03–2.71)], hyperbilirubinemia [HR 3.42 (95% CI: 1.87–6.25)] and ECOG-PS = 1 [HR 1.97 (95% CI: 1.19–3.26)] were found as independent indicators of poor overall survival. Dermatologic adverse effects were an indicator of good overall survival [HR 0.59 (95% CI: 0.38–0.92)].
Material and Methods
One hundred and fifty-four consecutive HCC patients treated with sorafenib in four different Spanish hospitals between August 2005 and October 2013 were analysed. Clinical, laboratory, and tumour features were obtained. Survival was calculated from the moment sorafenib treatment was initiated. Log-rank and Cox regression were used to analyse the ability of NLR to predict survival.
Conclusions
NLR is an independent prognostic indicator for overall survival in HCC patients treated with sorafenib.
000064386 540__ $$9info:eu-repo/semantics/openAccess$$aby$$uhttp://creativecommons.org/licenses/by/3.0/es/
000064386 592__ $$a1.942$$b2017
000064386 593__ $$aOncology$$c2017$$dQ1
000064386 655_4 $$ainfo:eu-repo/semantics/article$$vinfo:eu-repo/semantics/publishedVersion
000064386 700__ $$0(orcid)0000-0002-7119-2244$$aSerrano, Maria, Trinidad$$uUniversidad de Zaragoza
000064386 700__ $$aBustamante, Francisco Javier
000064386 700__ $$aIñarrairaegui, Mercedes
000064386 700__ $$aArenas, Juan, Ignacio
000064386 700__ $$aTestillano, Milagros
000064386 700__ $$0(orcid)0000-0003-4672-8083$$aLorente, Sara$$uUniversidad de Zaragoza
000064386 700__ $$aGil, Cristina
000064386 700__ $$ade la Torre, Manuel
000064386 700__ $$aGomez, Alejandra
000064386 700__ $$aSangro, Bruno
000064386 7102_ $$11007$$2610$$aUniversidad de Zaragoza$$bDpto. Medicina, Psiqu. y Derm.$$cArea Medicina
000064386 773__ $$g8, 61 (2017), 103077-103086$$pONCOTARGET$$tOncotarget$$x1949-2553
000064386 8564_ $$s991977$$uhttps://zaguan.unizar.es/record/64386/files/texto_completo.pdf$$yVersión publicada
000064386 8564_ $$s126282$$uhttps://zaguan.unizar.es/record/64386/files/texto_completo.jpg?subformat=icon$$xicon$$yVersión publicada
000064386 909CO $$ooai:zaguan.unizar.es:64386$$particulos$$pdriver
000064386 951__ $$a2019-07-09-12:26:10
000064386 980__ $$aARTICLE